1.
An. R. Acad. Farm
; 81(4): 293-296, oct.-dic. 2015.
Article
in Spanish
| IBECS
| ID: ibc-147345
ABSTRACT
No disponible
Subject(s)
Expert Testimony , DNA/analysis , DNA/pharmacology , Education, Pharmacy/trends , Technology, Pharmaceutical/education , Technology, Pharmaceutical/history , Technology, Pharmaceutical/methods , Pharmacy/methods , Pharmacy and Therapeutics Committee/ethics , Pharmacy and Therapeutics Committee/organization & administration , Pharmacy and Therapeutics Committee/standards , Drug Industry/economics , Drug Industry/education
2.
In. Anónimo. Programa Nacional de Medicamentos. La Habana, Ecimed, 2014. .
Monography
in Spanish
| CUMED
| ID: cum-56958
Subject(s)
Humans , Behind-the-Counter Drugs/pharmacology , Behind-the-Counter Drugs/supply & distribution , Good Dispensing Practices , Pharmacists/organization & administration , Pharmacy and Therapeutics Committee/ethics , Pharmacy and Therapeutics Committee/organization & administration , Pharmaceutical Services
3.
In. Anónimo. Programa Nacional de Medicamentos. La Habana, Ecimed, 2014. .
Monography
in Spanish
| CUMED
| ID: cum-56957
4.
BMJ
; 346: f1558, 2013 Mar 07.
Article
in English
| MEDLINE
| ID: mdl-23471487
5.
J Paediatr Child Health
; 48(5): 373-7, 2012 May.
Article
in English
| MEDLINE
| ID: mdl-22296413
ABSTRACT
A clinician and the chair of the hospital drug committee debate the merits of the use of palivizumab as prophylaxis against respiratory syncytial virus infection for a preterm baby with oxygen-dependent, chronic lung disease and discuss the issue of public funding of palivizumab. An ethicist comments on ethical aspects of the debate about cost-effectiveness.
Subject(s)
Antibodies, Monoclonal, Humanized/economics , Antiviral Agents/economics , Drug Costs , Financing, Organized/ethics , Health Care Rationing/ethics , Hospital Costs/ethics , Pharmacy and Therapeutics Committee/ethics , Antibodies, Monoclonal, Humanized/therapeutic use , Antiviral Agents/therapeutic use , Australia , Bronchopulmonary Dysplasia/complications , Cost-Benefit Analysis , Health Care Rationing/economics , Humans , Infant , Infant, Newborn , Infant, Premature , Male , Palivizumab , Respiratory Syncytial Virus Infections/complications , Respiratory Syncytial Virus Infections/prevention & control
6.
J Med Toxicol
; 7(2): 175-6, 2011 Jun.
Article
in English
| MEDLINE
| ID: mdl-21452075
7.
Pharmacoepidemiol Drug Saf
; 11(3): 247-52, 2002.
Article
in English
| MEDLINE
| ID: mdl-12058711
8.
Pharm. care Esp
; 3(3): 223-226, mayo-jun. 2001. tab
Article
in Spanish
| IBECS
| ID: ibc-168935
ABSTRACT
No disponible
